Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (83)

2023

  1. Antimicrobial resistance in Gram-negative bacilli in Spain: an experts’ view

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 65-81

  2. Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project)

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2291-2296

  3. The CARBA-MAP study: national mapping of carbapenemases in Spain (2014–2018)

    Frontiers in Microbiology, Vol. 14

2022

  1. Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

    Microbiology spectrum, Vol. 10, Núm. 5, pp. e0292722

  2. In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 3

  3. In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 11, pp. 3163-3172

2021

  1. A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2677-2699

  2. Clinical factors associated with reinfection versus relapse in infective endocarditis: Prospective cohort study

    Journal of Clinical Medicine, Vol. 10, Núm. 4, pp. 1-12

  3. Determining the burden of infectious diseases caused by carbapenem-resistant gram-negative bacteria in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 4, pp. 179-183

  4. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 2, pp. 370-379

  5. Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764

  6. Overview of virus and cancer relationships. Position paper

    Revista Espanola de Quimioterapia, Vol. 34, Núm. 6, pp. 525-555

2020

  1. Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: A multidisciplinary opinion document

    Revista Espanola de Quimioterapia, Vol. 33, Núm. 1, pp. 49-67

  2. First national survey of the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 410-416

  3. Neck infection after allogenic hematopoietic progenitors transplantation

    Revista Espanola de Quimioterapia, Vol. 33, Núm. 2, pp. 130-136

  4. Prediction of poor outcome in Clostridioides difficile infection: A multicentre external validation of the toxin B amplification cycle

    Anaerobe, Vol. 61

  5. Recommendations for the diagnosis and treatment of clostridioides difficile infection: An official clinical practice guideline of the spanish society of chemotherapy (SEQ), spanish society of internal medicine (SEMI) and the working group of postoperative infection of the spanish society of anesthesia and reanimation (SEDAR)

    Revista Espanola de Quimioterapia, Vol. 33, Núm. 2, pp. 151-175

  6. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

  7. WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain

    JAC-Antimicrobial Resistance, Vol. 2, Núm. 4

2019

  1. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study

    International Journal of Antimicrobial Agents, Vol. 53, Núm. 5, pp. 682-688